Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibody”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07609576
What this trial is testing

Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.

Who this might be right for
Lymphoma NeoplasmsMyeloma MultipleSevere Infection+3 more
Infanta Leonor University Hospital 350
Large-scale testing (Phase 3)Study completedNCT02393859
What this trial is testing

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Leukemia, Acute Lymphoblastic
Amgen 111
Testing effectiveness (Phase 2)Looking for participantsNCT06900010
What this trial is testing

Evaluate CM336 in Adults With Autoimmune Bullous Disease

Who this might be right for
Autoimmune Bullous Disease
Shandong First Medical University 30
Early research (Phase 1)Study completedNCT03340766
What this trial is testing

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05102214
What this trial is testing

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsNon-small Cell Lung Cancer
Shanghai Henlius Biotech 150
Early research (Phase 1)Looking for participantsNCT07195916
What this trial is testing

Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Solid TumorsHematologic Malignancies
Incyte Corporation 280
Large-scale testing (Phase 3)Looking for participantsNCT07648264
What this trial is testing

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Who this might be right for
Secondary Immune Deficiency
CSL Behring 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT06508606
What this trial is testing

AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
West China Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT04492033
What this trial is testing

CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Who this might be right for
P1b: Advanced Solid TumorsP2: Biliary Tract Cancer
Handok Inc. 41
Very early researchNot Yet RecruitingNCT07066436
What this trial is testing

ImmunoMRI for Assessment of Tumor-associated Macrophages

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Medical University of Vienna 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253
What this trial is testing

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Who this might be right for
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University 47
Large-scale testing (Phase 3)Study completedNCT00836654
What this trial is testing

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Who this might be right for
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)Malignant Ascites
Neovii Biotech 258
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Early research (Phase 1)Active Not RecruitingNCT06369467
What this trial is testing

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Who this might be right for
Food Allergy
Regeneron Pharmaceuticals 6
Early research (Phase 1)Looking for participantsNCT07101328
What this trial is testing

LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Who this might be right for
Lymphoma, Non-HodgkinB-cell LymphomaLymphoma, Large B-Cell, Diffuse+4 more
Eli Lilly and Company 215
Early research (Phase 1)Active Not RecruitingNCT03399799
What this trial is testing

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 279
Testing effectiveness (Phase 2)UnknownNCT06441019
What this trial is testing

Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab
Fudan University 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523
What this trial is testing

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca 212
Large-scale testing (Phase 3)Looking for participantsNCT06980480
What this trial is testing

Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Who this might be right for
Multiple MyelomaSecondary Immunodeficiency
Takeda 183
Next Page